Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
The chart shows the growth of an initial investment of $10,000 in Avanos Medical, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Avanos Medical, Inc. (AVNS) has returned 24.11% so far this year and 5.68% over the past 12 months. Looking at the last ten years, AVNS has achieved an annualized return of -14.09%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Avanos Medical, Inc. (AVNS) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.51% | 6.33% | 1.74% | -0.36% | ||||||||
| 2025 | 6.89% | -10.58% | -5.60% | -12.30% | -0.32% | -2.24% | -7.53% | 6.42% | -2.86% | -3.39% | 6.05% | -3.52% |
| 2024 | -13.71% | -3.63% | 7.62% | -9.51% | 10.30% | -0.70% | 19.24% | 1.42% | -0.50% | -22.33% | 2.51% | -17.04% |
| 2023 | 12.03% | -8.12% | 6.14% | -0.24% | -16.84% | 4.45% | -3.43% | -12.91% | -4.67% | -9.02% | 14.93% | 4.67% |
| 2022 | -13.25% | 16.38% | -4.99% | -13.14% | -1.61% | -5.10% | 4.34% | -12.69% | -10.66% | 0.32% | 20.20% | -0.04% |
| 2021 | -2.29% | 1.43% | -6.68% | -1.82% | -7.94% | -9.21% | 4.09% | -13.07% | -6.11% | 1.71% | -4.92% | 13.04% |
| 2020 | -18.59% | 17.77% | -17.67% | 21.81% | -4.09% | 1.34% | 4.07% | 4.79% | 3.46% | 6.73% | 18.28% | 6.52% |
| 2019 | 3.43% | 3.36% | -10.01% | -2.49% | -12.07% | 15.65% | -8.18% | -18.66% | 13.89% | 17.00% | -21.71% | -2.80% |
| 2018 | -13.30% | 30.71% | -5.09% | -17.73% | -16.25% | -7.31% |
The charts below present risk-adjusted performance metrics for Avanos Medical, Inc. (AVNS) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of AVNS compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Avanos Medical, Inc. volatility is 1.73%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.15B | 1.69B | 1.79B | 1.59B | 1.67B | 1.80B | 1.83B |
| Equity Attributable To Parent (USD) | 828.50M | 1.24B | 1.29B | 1.26B | 1.26B | 1.27B | 1.30B |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - |
| Equity (USD) | 828.50M | 1.24B | 1.29B | 1.26B | 1.26B | 1.27B | 1.30B |
| Other Non-current Liabilities (USD) | 34.50M | 62.10M | 83.60M | 61.50M | 70.00M | - | 21.90M |
| Long-term Debt (USD) | 125.30M | 159.40M | 226.30M | 130.00M | 180.00M | - | 250.00M |
| Noncurrent Liabilities (USD) | 159.80M | 221.50M | 309.90M | 191.50M | 250.00M | 321.90M | 271.90M |
| Other Current Liabilities (USD) | 111.60M | 178.30M | 117.90M | 82.80M | 98.70M | 129.50M | 94.40M |
| Accounts Payable (USD) | 54.30M | 56.30M | 67.90M | 56.40M | 67.60M | 83.00M | 169.90M |
| Current Liabilities (USD) | 165.90M | 234.60M | 185.80M | 139.20M | 166.30M | 212.50M | 264.30M |
| Liabilities (USD) | 325.70M | 456.10M | 495.70M | 330.70M | 416.30M | 534.40M | 536.20M |
| Other Non-current Assets (USD) | 537.80M | 848.70M | 872.20M | 866.70M | 872.60M | 892.30M | 797.50M |
| Intangible Assets (USD) | 112.30M | 239.50M | 251.00M | 141.20M | 157.70M | 184.30M | 168.20M |
| Fixed Assets (USD) | 110.70M | 117.20M | 163.90M | 168.10M | 175.30M | 184.50M | 154.10M |
| Noncurrent Assets (USD) | 760.80M | 1.21B | 1.29B | 1.18B | 1.21B | 1.26B | 1.12B |
| Other Current Assets (USD) | 121.80M | 181.00M | 141.60M | 137.10M | 130.40M | 392.60M | 592.20M |
| Inventory (USD) | 138.80M | 163.20M | 190.30M | 150.30M | 168.90M | 145.90M | 121.40M |
| Accounts Receivable (USD) | 132.80M | 142.80M | 167.90M | 131.20M | 167.90M | - | - |
| Current Assets (USD) | 393.40M | 487.00M | 499.80M | 418.60M | 467.20M | 538.50M | 713.60M |
| Assets (USD) | 1.15B | 1.69B | 1.79B | 1.59B | 1.67B | 1.80B | 1.83B |
Avanos Medical reported Q2 2025 financial results, highlighting strong performance in Specialty Nutrition Systems and Pain Management segments, while divesting its hyaluronic acid product line. The company maintained full-year revenue and earnings guidance despite tariff challenges and leadership changes.
The report provides a comprehensive analysis of the United States market for syringes, needles, and urinary catheters, including market data, company profiles, and industry trends from 2018 to 2033.
The global bio pharma buffer market is expected to grow from $1.1 billion in 2023 to $2.4 billion by 2033, driven by the rising demand for biopharmaceuticals and the need for high-quality buffers in drug development and manufacturing.
The global pain management devices market is projected to grow at a CAGR of 21.5% from 2024 to 2031, driven by the increasing prevalence of chronic diseases and the rising demand for non-invasive pain management solutions.
Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.
Avanos Medical (AVNS) delivered earnings and revenue surprises of +4.76% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) delivered earnings and revenue surprises of -9.52% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?